Understanding the Angiogenic Characteristics of Clinical-Grade Mesenchymal Stromal Cells Isolated from Human Umbilical Cord.
Charlotte CarcopinoElisa RossiMiryam MebarkiDivina El HamaouiPascale GaussemJérôme LargheroDavid M SmadjaAudrey CrasPublished in: Stem cell reviews and reports (2024)
Addressing the challenges in managing ischemic tissue repair and remodelling remains a prominent clinical concern. Current research is heavily concentrated on identifying innovative cell-based therapies with the potential to enhance revascularization in patients affected by these diseases. We have previously developed and validated a manufacturing process for human umbilical cord mesenchymal stromal cells (UC-MSCs)-based cell therapy medicinal product, according to Good Manufacturing Practices. In this study, we demonstrate that these UC-MSCs enhance the proliferation and migration of endothelial cells and the formation of capillary structures. Moreover, UC-MSCs and endothelial cells interact, allowing UC-MSCs to acquire a perivascular cell phenotype and consequently provide direct support to the newly formed vascular network. This characterization of the proangiogenic properties of this UC-MSCs based-cell therapy medicinal product is an essential step for its therapeutic assessment in the clinical context of vascular regeneration.
Keyphrases
- cell therapy
- mesenchymal stem cells
- umbilical cord
- endothelial cells
- bone marrow
- stem cells
- end stage renal disease
- high glucose
- healthcare
- peritoneal dialysis
- chronic kidney disease
- primary care
- newly diagnosed
- ejection fraction
- prognostic factors
- vascular endothelial growth factor
- climate change
- coronary artery disease
- percutaneous coronary intervention
- blood brain barrier
- single cell
- brain injury